| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
| The sector is experiencing a period of significant advancements and strong stock performance, particularly from key players such as CVS Health, Pfizer, and Novo Nordisk. The impact of midterm elections has led to positive market movements, with investor focus shifting towards innovation in drugs and healthcare solutions. Despite broader market volatility, healthcare stocks have demonstrated resilience and growth, capturing both investor attention and optimism. The sector remains a focal point for discussions on regulatory changes and strategic expansions in response to market demands. The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at 1.8 is very bullish. The market sentiment at 0.5 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.XLV is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for Health Care sector is at 0.9, and the negative at -0.5 on 2026-11-04. The forces of Sentiment towards Fundamentals (2.2), Sector Price Trend (1.8), Valuation Sentiment (1.1), and Option Sentiment (0.3) will drive up the price. The forces of Broad Market Trend (-0.3), Price Level Sentiment (-1), and Market Risk Appetite (-1.4) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice Sector Rotation Notification
| XLV | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-04 | 2%(1.7%) | 189.68 | 2.92% | 101 | 77 | 69 | 3.06% | 0.61% | 1.8 | 0.6 | 1.1% | 0.5 | Long | 70% | 2.2 | 4.1 |
| 2026-11-03 | 1%(1.7%) | 184.04 | 2.95% | 81 | 74 | 52 | -0.33% | 0.22% | 1 | -0.2 | 0.3% | 0.1 | Wait | 50% | 1.6 | 5.5 |
| 2026-11-02 | 1%(1.7%) | 184.65 | 3.03% | 87 | 79 | 42 | -0.1% | 0.5% | 1.3 | 0 | 0.6% | 0.4 | Long | 55% | 1.8 | 3.1 |
| 2026-11-01 | 2%(1.7%) | 1.3 | 0.3 | 1.6 | 2.5 | |||||||||||
| 2026-10-31 | 1%(1.7%) | 1.3 | 0.3 | 1.6 | 5.5 | |||||||||||
| 2026-10-30 | 2%(1.7%) | 184.84 | 3.08% | 91 | 80 | 57 | 0.42% | 0.45% | 1.3 | 0.2 | 1.2% | 0.3 | Long | 55% | 1.8 | 3.3 |
| 2026-10-29 | 3%(1.6%) | 184.07 | 3.05% | 92 | 82 | 71 | 2.4% | 0.39% | 1.1 | 0.4 | 1.1% | 0.6 | Long | 55% | 1.8 | 5.1 |
| 2026-10-28 | 2%(1.4%) | 179.76 | 2.97% | 78 | 76 | 57 | 0.32% | 0.34% | 0.7 | -0 | 0.4% | 0.3 | Long | 55% | 1.7 | 2.3 |
| 2026-10-27 | 1%(1.4%) | 179.19 | 2.9% | 78 | 77 | 40 | -0.04% | 0.39% | 0.6 | 0 | 0.3% | 0.6 | Long | 55% | 2.1 | 0.2 |
| 2026-10-26 | 1%(1.4%) | 179.27 | 2.81% | 82 | 76 | 52 | -0.01% | 0.45% | 0.9 | -0.1 | 0.5% | 0.4 | Wait | 50% | 2.2 | 2.1 |
| Long is the preferred trading strategy with 70% chance of being right. Both trend sentiment and hourly trend are very strong. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Health Care Sector Check-Up: What Analysts Are Saying Right Now Mon. Sep 29, 2025 | ||
| Market News | ||
| 1 (7) Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know The Wegovy maker raised its outlook again and the stock jumped. But its CEO refused to forecast next year, and handed investors six clues instead. (https://www.fool.com/) Wed. Nov 4, 2026 | ||
| 2 (8) Healthcare Stocks Bounce on Midterm Results. A Bull Market Case Is Developing. The stocks of big operators in state Medicaid programs, Affordable Care Act markets and hospital groups all jumped. (https://www.barrons.com/) Wed. Nov 4, 2026 | ||
| 3 (8) Healthcare Stocks Bounce on Midterm Results. A Bull Market Case Is Developing. The stocks of big operators in state Medicaid programs, Affordable Care Act markets and hospital groups all jumped. (https://www.barrons.com/) Wed. Nov 4, 2026 | ||
| 4 (6) CVS Health plans to split itself up. Here's why a breakup could make sense now Analysts say that after a roughly two-year turnaround the company's retail pharmacy business and other units may be strong enough to stand on their own. (https://www.cnbc.com/) Wed. Nov 4, 2026 | ||
| 5 (7) Health insurers, hospitals rally after sweeping midterm win for Democrats Nov 4 (Reuters) - Shares of Medicaid-focused US health insurers and hospital operators rose in early trading on Wednesday as Democrats' sweep of the Senate and House of Representatives in the midterm (https://finance.yahoo.com/) Wed. Nov 4, 2026 | ||
| 6 (3) Novo Nordisk CEO says CVS breakup has no material impact on the weight-loss drug giant A CVS breakup will be a big deal for healthcare players. (https://finance.yahoo.com/) Wed. Nov 4, 2026 | ||
| 7 (-6) CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup. The healthcare giant surprised analysts with the decision to separate its business. Its stock is down. (https://www.marketwatch.com/) Wed. Nov 4, 2026 | ||
| 8 (7) Hospital stocks rally while drugmakers brace for scrutiny. Here’s what the Democratic wave means for healthcare. The Democratic victory in the midterm elections could be a huge boon to the nation’s largest hospitals. (https://www.marketwatch.com/) Wed. Nov 4, 2026 | ||
| 9 (6) Novo Nordisk Stock Shrugs Off Eli Lilly Threat as Weight-Loss Pill Shines in Earnings Novo Nordisk stock has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful. (https://www.barrons.com/) Wed. Nov 4, 2026 | ||
| 10 (8) Novo Nordisk CEO: Wegovy pill 'exceeded our expectations' The Wegovy pill looks like a win for Novo Nordisk. (https://finance.yahoo.com/) Wed. Nov 4, 2026 | ||
| 11 (6) Novo Nordisk Weight-Loss Pill Sales Soar. One Other Earnings Revelation Boosting the Stock. Novo Nordisk stock has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful. (https://www.barrons.com/) Wed. Nov 4, 2026 | ||
| 12 (5) Novo Nordisk Weight-Loss Pill Sales Soar. One Other Earnings Revelation Boosting the Stock. Novo Nordisk stock has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful. (https://www.barrons.com/) Wed. Nov 4, 2026 | ||
| 13 (7) Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market Pfizer CEO Albert Bourla says the company can replicate its past success as it leads a renewed push into the weight-loss drug market. (https://www.barrons.com/) Wed. Nov 4, 2026 | ||
| 14 (5) CVS Plans to Break Up $117 Billion Healthcare Conglomerate CVS Health Corp. plans to spin off its retail pharmacy business in one of the biggest-ever breakups in the healthcare industry. (https://www.bloomberg.com/) Wed. Nov 4, 2026 | ||
| 15 (-5) CVS to split off drugstore business in major breakup of healthcare giant The move would reverse the company's $78 billion acquisition of Aetna and dismantle the vertically integrated healthcare conglomerate it created in 2018. (https://www.cnbc.com/) Wed. Nov 4, 2026 | ||
| 16 (6) CVS announces plan to split into 2 companies, separating pharmacy from insurance CVS announced plans to separate into two independent, publicly traded companies on Wednesday, reshaping one of the largest healthcare companies in the US. (https://finance.yahoo.com/) Wed. Nov 4, 2026 | ||
| 17 (8) Beleaguered Novo offers relief to investors, thanks to Wegovy pill Novo Nordisk’s stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss-drug pill that has been launched this year. (https://www.marketwatch.com/) Wed. Nov 4, 2026 | ||
| 18 (5) CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup. The healthcare giant surprised analysts with the decision to separate its business. (https://www.marketwatch.com/) Wed. Nov 4, 2026 | ||
| 19 (5) CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup. The healthcare giant surprised analysts with the decision to separate its business. (https://www.marketwatch.com/) Wed. Nov 4, 2026 | ||
| 20 (-4) Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It. No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle. (https://www.wsj.com/) Wed. Nov 4, 2026 | ||
| 21 () CVS Earnings Will Be About One Federal Drug Program Wall Street expects CVS to report third-quarter adjusted earnings of $1.65 a share, up from $1.60 a share in the same quarter last year. (https://www.barrons.com/) Tue. Nov 3, 2026 | ||
| 22 () Pfizer CEO Says Covid Is ‘Irrelevant.’ He’s Betting on Cancer and Weight-Loss Drugs. Pfizer raises full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products. (https://www.barrons.com/) Tue. Nov 3, 2026 | ||
| 23 () CVS Plans to Break Up Healthcare Conglomerate, Reports Say CVS Health Corp. is planning to spin off its retail pharmacy business, according to media reports, in what would be one of the biggest-ever breakups in the healthcare industry. (https://www.bloomberg.com/) Tue. Nov 3, 2026 | ||
| 24 () CVS Jumps on Report It Plans to Break Up Health Conglomerate CVS Health Corp. is discussing plans to spin off its retail pharmacy business, according to the Financial Times, a shocking retreat for the country’s largest drugstore chain. (https://finance.yahoo.com/) Tue. Nov 3, 2026 | ||
| 25 () Pfizer CEO Says Covid Is ‘Irrelevant.’ He’s Betting on Cancer and Weight-Loss Drugs. Pfizer raises full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products. (https://www.barrons.com/) Tue. Nov 3, 2026 | ||
| 26 (5) Health and Longevity Spending Is Rising. Here’s How to Plan for It. AgeLab’s Joseph Coughlin suggests creating three “health portfolios” to fund spending for increasingly sophisticated and expensive health and wellness programs. (https://www.barrons.com/) Tue. Nov 3, 2026 | ||
| 27 (7) Apple Launches Beta Versions of Watch AI Listening Tools, New Health App Apple Inc. rolled out the first developer beta versions of iOS 27.3 and watchOS 27.3 on Tuesday, putting new features like always-listening artificial intelligence tools, its AI platform for China and a fresh Health app into widespread testing. (https://www.bloomberg.com/) Tue. Nov 3, 2026 | ||
| 28 (7) Pfizer Bets on Cancer and Weight-Loss Drugs in Post-Pandemic Second Act Pfizer raises full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products. (https://www.barrons.com/) Tue. Nov 3, 2026 | ||
| 29 (7) Pfizer Bets on Cancer and Weight-Loss Drugs in Post-Pandemic Second Act Pfizer raises full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products. (https://www.barrons.com/) Tue. Nov 3, 2026 | ||
| 30 (8) Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally? The healthcare stock may finally have the catalyst that it needs to take off before the end of the year. (https://www.fool.com/) Tue. Nov 3, 2026 | ||
| 31 (8) Pfizer increases annual profit forecast amid solid demand for blood thinner drug Investing.com - Pfizer has lifted its full-year profit forecast, thanks largely to strong demand for its blood thinner Eliquis. (https://finance.yahoo.com/) Tue. Nov 3, 2026 | ||
| 32 (0) Pfizer Q3 preview: Goldman sees in-line quarter, pipeline in focus Pfizer Q3 preview: Goldman sees in-line quarter, pipeline in focus (https://www.investing.com/) Tue. Nov 3, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA